Propanc Biopharma, Inc. (PPCB)
| Market Cap | 2.30M -98.1% |
| Revenue (ttm) | n/a |
| Net Income | -19.29M |
| EPS | -32.41 |
| Shares Out | 2.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,354 |
| Open | 1.070 |
| Previous Close | 1.040 |
| Day's Range | 0.950 - 1.080 |
| 52-Week Range | 0.950 - 270.250 |
| Beta | 3.27 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 29, 2026 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the Un... [Read more]
Financial Performance
Financial StatementsNews
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
MELBOURNE, Australia, July 21, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma registers to sell 2.5M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.5M shares of common stock. The company is not selling any…
Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial
Propanc Biopharma (PPCB) announced it has signed a memorandum of understanding with Avance Clinical. The MOU sets out the shared intent of Propanc and Avance to work together to support…
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma initiates share repurchase program
Propanc Biopharma (PPCB) announced it has initiated a share repurchase program authorizing the company to repurchase a first tranche of up to $500,000 over the next 30-day period. Published first…
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc CEO visits European manufacturer ahead of drug production plan
Propanc Biopharma (PPCB) announced that CEO James Nathanielsz toured a European contract development and manufacturing organization’s facility in preparation for the production of the company’s lead d...
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma announces $5M share repurchase program
Propanc Biopharma (PPCB) announced it has approved a share repurchase program authorizing the company to repurchase up to $5M of its common stock.
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chron...
Propanc Biopharma engages European CDMO for GMP production of PRP
Propanc Biopharma (PPCB) announced that a contract and development manufacturing organization, or CDMO, has been engaged for the GMP manufacture of the company’s lead asset, PRP, for the upcoming Phas...
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
MELBOURNE, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chron...
Propanc Biopharma Inc trading halted, news pending
19:50 EDT Propanc Biopharma (PPCB) Inc trading halted, news pending
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chron...
Propanc Biopharma announces 1-for-25 reverse stock split
Propanc Biopharma (PPCB) announced that its board of directors on March 16 approved a 1-for-25 reverse stock split of the company’s issued and outstanding shares of common stock, par value…
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chro...
Propanc Biopharma files to sell 15M shares of common stock for holders
17:32 EDT Propanc Biopharma (PPCB) files to sell 15M shares of common stock for holders
Propanc Biopharma signs multi-year collaboration with Spanish universities
Propanc Biopharma (PPCB) announced that a multi-year joint research collaboration agreement has been established with the Universities of Jaen and Granada, Spain. “As we enter an exciting phase for th...
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.
Propanc Biopharma announces highlights of PRP
Propanc Biopharma (PPCB) announced highlights of PRP, its lead proenzyme therapy. The company said, “Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the...
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chr...
Propanc Biopharma executes service agreement with FyoniBio
Propanc Biopharma (PPCB) announced that management has executed a service agreement with FyoniBio, a German Contract Development Organization, CDO, based in Berlin for establishing and validating a li...
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients